NASDAQ:AEZS

Aeterna Zentaris Competitors

$0.39

-0.02 (-4.87 %)

(As of 11/25/2020 12:00 AM ET)

Add

Compare

Today's Range

$0.39

Now: $0.39▼

$0.41

50-Day Range

$0.30

MA: $0.35▼

$0.42

52-Week Range

$0.29

Now: $0.39▼

$1.54

Volume981,407 shs

Average Volume2.03 million shs

Market Capitalization$24.50 million

P/E RatioN/A

Dividend YieldN/A

Beta2.05

Aeterna Zentaris (NASDAQ:AEZS) Vs. SBPH, VRNA, CLSD, OBSV, KZIA, and ARAV

Should you be buying AEZS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Aeterna Zentaris, including Spring Bank Pharmaceuticals (SBPH), Verona Pharma (VRNA), Clearside Biomedical (CLSD), ObsEva (OBSV), Kazia Therapeutics (KZIA), and Aravive (ARAV).

Aeterna Zentaris vs. Spring Bank Pharmaceuticals Stock

Spring Bank Pharmaceuticals (NASDAQ:SBPH) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Spring Bank Pharmaceuticals and Aeterna Zentaris' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spring Bank Pharmaceuticals	N/A	N/A	$-24,100,000.00	($1.47)	-3.80
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A

Aeterna Zentaris has higher revenue and earnings than Spring Bank Pharmaceuticals.

Insider & Institutional Ownership

17.2% of Spring Bank Pharmaceuticals shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. 12.7% of Spring Bank Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Spring Bank Pharmaceuticals and Aeterna Zentaris' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spring Bank Pharmaceuticals	N/A	-89.89%	-52.89%
Aeterna Zentaris	-369.10%	-125.54%	-21.45%

Analyst Recommendations

This is a summary of current ratings for Spring Bank Pharmaceuticals and Aeterna Zentaris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spring Bank Pharmaceuticals	0	3	1	0	2.25
Aeterna Zentaris	0	0	0	0	N/A

Spring Bank Pharmaceuticals presently has a consensus price target of $1.7333, indicating a potential downside of 68.94%. Given Spring Bank Pharmaceuticals' higher possible upside, equities research analysts clearly believe Spring Bank Pharmaceuticals is more favorable than Aeterna Zentaris.

Risk & Volatility

Spring Bank Pharmaceuticals has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Summary

Spring Bank Pharmaceuticals beats Aeterna Zentaris on 6 of the 11 factors compared between the two stocks.

Aeterna Zentaris vs. Verona Pharma Stock

Verona Pharma (NASDAQ:VRNA) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Verona Pharma and Aeterna Zentaris' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verona Pharma	N/A	N/A	$-40,780,000.00	($3.10)	-2.34
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A

Aeterna Zentaris has higher revenue and earnings than Verona Pharma.

Insider & Institutional Ownership

54.5% of Verona Pharma shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Verona Pharma and Aeterna Zentaris' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Verona Pharma	N/A	-115.93%	-73.68%
Aeterna Zentaris	-369.10%	-125.54%	-21.45%

Analyst Recommendations

This is a summary of current ratings for Verona Pharma and Aeterna Zentaris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verona Pharma	0	0	4	0	3.00
Aeterna Zentaris	0	0	0	0	N/A

Verona Pharma presently has a consensus price target of $22.75, indicating a potential upside of 213.36%. Given Verona Pharma's higher possible upside, equities research analysts clearly believe Verona Pharma is more favorable than Aeterna Zentaris.

Risk & Volatility

Verona Pharma has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Aeterna Zentaris vs. Clearside Biomedical Stock

Clearside Biomedical (NASDAQ:CLSD) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Valuation and Earnings

This table compares Clearside Biomedical and Aeterna Zentaris' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clearside Biomedical	$2.17 million	43.67	$-30,770,000.00	($0.81)	-2.42
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A

Aeterna Zentaris has lower revenue, but higher earnings than Clearside Biomedical.

Insider & Institutional Ownership

25.2% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. 13.1% of Clearside Biomedical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Clearside Biomedical and Aeterna Zentaris' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Clearside Biomedical	-144.47%	-153.41%	-65.29%
Aeterna Zentaris	-369.10%	-125.54%	-21.45%

Analyst Recommendations

This is a summary of current ratings for Clearside Biomedical and Aeterna Zentaris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Clearside Biomedical	0	2	3	0	2.60
Aeterna Zentaris	0	0	0	0	N/A

Clearside Biomedical presently has a consensus price target of $5.75, indicating a potential upside of 193.37%. Given Clearside Biomedical's higher possible upside, equities research analysts clearly believe Clearside Biomedical is more favorable than Aeterna Zentaris.

Risk & Volatility

Clearside Biomedical has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Aeterna Zentaris vs. ObsEva Stock

ObsEva (NASDAQ:OBSV) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Insider & Institutional Ownership

48.5% of ObsEva shares are owned by institutional investors. Comparatively, 2.1% of Aeterna Zentaris shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for ObsEva and Aeterna Zentaris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	1	1	4	0	2.50
Aeterna Zentaris	0	0	0	0	N/A

ObsEva presently has a consensus price target of $14.3333, indicating a potential upside of 635.04%. Given ObsEva's higher possible upside, equities research analysts clearly believe ObsEva is more favorable than Aeterna Zentaris.

Valuation and Earnings

This table compares ObsEva and Aeterna Zentaris' gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	$-108,790,000.00	($2.49)	-0.78
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A

Aeterna Zentaris has higher revenue and earnings than ObsEva.

Profitability

This table compares ObsEva and Aeterna Zentaris' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-195.77%	-86.73%
Aeterna Zentaris	-369.10%	-125.54%	-21.45%

Risk & Volatility

ObsEva has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.

Aeterna Zentaris vs. Kazia Therapeutics Stock

Aeterna Zentaris (NASDAQ:AEZS) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

2.1% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 11.9% of Kazia Therapeutics shares are owned by institutional investors. 1.0% of Kazia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aeterna Zentaris and Kazia Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aeterna Zentaris	0	0	0	0	N/A
Kazia Therapeutics	0	0	0	0	N/A

Earnings and Valuation

This table compares Aeterna Zentaris and Kazia Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A
Kazia Therapeutics	$710,000.00	131.24	$-8,370,000.00	($1.30)	-7.58

Aeterna Zentaris has higher earnings, but lower revenue than Kazia Therapeutics.

Profitability

This table compares Aeterna Zentaris and Kazia Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aeterna Zentaris	-369.10%	-125.54%	-21.45%
Kazia Therapeutics	N/A	N/A	N/A

Volatility and Risk

Aeterna Zentaris has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500.

Summary

Kazia Therapeutics beats Aeterna Zentaris on 8 of the 10 factors compared between the two stocks.

Aeterna Zentaris vs. Aravive Stock

Aeterna Zentaris (NASDAQ:AEZS) and Aravive (NASDAQ:ARAV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, valuation, dividends, profitability and analyst recommendations.

Institutional & Insider Ownership

2.1% of Aeterna Zentaris shares are owned by institutional investors. Comparatively, 51.2% of Aravive shares are owned by institutional investors. 30.5% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Aeterna Zentaris and Aravive, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aeterna Zentaris	0	0	0	0	N/A
Aravive	0	1	6	0	2.86

Aravive has a consensus target price of $26.20, indicating a potential upside of 352.50%. Given Aravive's higher possible upside, analysts plainly believe Aravive is more favorable than Aeterna Zentaris.

Earnings and Valuation

This table compares Aeterna Zentaris and Aravive's revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aeterna Zentaris	$530,000.00	46.23	$-6,040,000.00	N/A	N/A
Aravive	$4.75 million	19.61	$-18,220,000.00	($1.57)	-3.69

Aeterna Zentaris has higher earnings, but lower revenue than Aravive.

Profitability

This table compares Aeterna Zentaris and Aravive's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aeterna Zentaris	-369.10%	-125.54%	-21.45%
Aravive	N/A	-47.21%	-39.11%

Volatility and Risk

Aeterna Zentaris has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Aravive has a beta of 3.26, suggesting that its share price is 226% more volatile than the S&P 500.

Summary

Aravive beats Aeterna Zentaris on 8 of the 12 factors compared between the two stocks.